Repurposing the antihistamine terfenadine for antimicrobial activity against staphylococcus aureus

Journal of Medicinal Chemistry

Volumn 57, Issue 20, 2014, Pages 8540-8562

  Perlmutter, Jessamyn I ^a   Forbes, Lauren T ^a   Krysan, Damian J ^a   Ebsworth Mojica, Katherine ^a   Colquhoun, Jennifer M ^a   Wang, Jenna L ^b   Dunman, Paul M ^a   Flaherty, Daniel P ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 (TERT BUTYL)PHENYL)[4 (HYDROXYDIPHENYLMETHYL)PIPERIDIN 1 YL]METHANONE; 1 (4 BROMOPHENYL) 4 [4 (HYDROXYDIPHENYLMETHYL)PIPERIDIN 1 YL]BUTAN 1 OL; 1 (4 BROMOPHENYL) 4 [4 (HYDROXYDIPHENYLMETHYL)PIPERIDIN 1 YL]BUTAN 1 ONE; 1 (4 CHLOROPHENYL) 4 [4 (HYDROXYDIPHENYLMETHYL)PIPERIDIN 1 YL]BUTAN 1 OL; 1 (4 CHLOROPHENYL) 4 [4 (HYDROXYDIPHENYLMETHYL)PIPERIDIN 1 YL]BUTAN 1 ONE; 1 (4 FLUOROPHENYL) 4 [4 (HYDROXYDIPHENYLMETHYL)PIPERIDIN 1 YL]BUTAN 1 OL; 1 (4 FLUOROPHENYL) 4 [4 (HYDROXYDIPHENYLMETHYL)PIPERIDIN 1 YL]BUTAN 1 ONE; 1 (4 ISO PROPYLPHENYL) 4 [4 (HYDROXYDIPHENYLMETHYL)PIPERIDIN 1 YL]BUTAN 1 OL; 1 (4 METHOXYPHENYL) 4 [4 (HYDROXYDIPHENYLMETHYL)PIPERIDIN 1 YL]BUTAN 1 OL; 1 (4 METHOXYPHENYL) 4 [4 (HYDROXYDIPHENYLMETHYL)PIPERIDIN 1 YL]BUTAN 1 ONE; 1 (4 METHYL) 4 [4 (HYDROXYDIPHENYLMETHYL)PIPERIDIN 1 YL]BUTAN 1 ONE; 1 PHENYL 4 [4 (HYDROXYDIPHENYLMETHYL)PIPERIDIN 1 YL]BUTAN 1 OL; 1 PHENYL 4 [4 (HYDROXYDIPHENYLMETHYL)PIPERIDIN 1 YL]BUTAN 1 ONE; 1 [4 (ISO PROPYL)PHENYL) 4 (4 (HYDROXYDIPHENYLMETHYL)PIPERIDIN 1 YL]BUTAN 1 ONE; 1 [4 (METHYL)PHENYL) 4 (4 (HYDROXYDIPHENYLMETHYL)PIPERIDIN 1 YL]BUTAN 1 ONE; 1 [4 (TERT BUTYL)PHENYL) 2 (4 (HYDROXYDIPHENYLMETHYL)PIPERIDIN 1 YL]ETHANOL 1 OL; 1 [4 (TERT BUTYL)PHENYL) 2 (4 (HYDROXYDIPHENYLMETHYL)PIPERIDIN 1 YL]ETHANONE 1 ONE; 1 [4 (TERT BUTYL)PHENYL) 3 (4 (HYDROXYDIPHENYLMETHYL)PIPERIDIN 1 YL]PROPAN 1 OL; 1 [4 (TERT BUTYL)PHENYL) 3 (4 (HYDROXYDIPHENYLMETHYL)PIPERIDIN 1 YL]PROPAN 1 ONE; 1 [4 (TERT BUTYL)PHENYL) 4 (4 (HYDROXYDIPHENYLMETHYL)PIPERIDIN 1 YL]BUTAN 1 OL; 1 [4 (TERT BUTYL)PHENYL) 4 (4 (HYDROXYDIPHENYLMETHYL)PIPERIDIN 1 YL]BUTAN 1 ONE; 1 [4 (TERT BUTYL)PHENYL) 5 (4 (HYDROXYDIPHENYLMETHYL)PIPERIDIN 1 YL]PENTAN 1 OL; 1 [4 (TERT BUTYL)PHENYL) 5 (4 (HYDROXYDIPHENYLMETHYL)PIPERIDIN 1 YL]PENTAN 1 ONE; ANTIBIOTIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); METHYL 4 [1 HYDROXY 4 (4 (HYDROXYDIPHENYLMETHYL)PIPERIDIN 1 YL)BUTYL]BENZOATE; TERFENADINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; [1 ((1,1' BIPHENYL) 4 YLMETHYL)PIPERIDIN 4 YL]DIPHENYLMETHANOL; ANTIINFECTIVE AGENT; DNA TOPOISOMERASE IV; ERG1 POTASSIUM CHANNEL; GYRASE INHIBITOR; HISTAMINE H1 RECEPTOR ANTAGONIST; POTASSIUM CHANNEL HERG;

ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG POTENCY; DRUG REPOSITIONING; DRUG STRUCTURE; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; IC50; LIPOPHILICITY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; STAPHYLOCOCCUS AUREUS; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; SUZUKI REACTION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; HUMAN; METABOLISM; MICROBIAL SENSITIVITY TEST; SYNTHESIS;

ANTI-BACTERIAL AGENTS; CHEMISTRY TECHNIQUES, SYNTHETIC; DNA GYRASE; DNA TOPOISOMERASE IV; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHER-A-GO-GO POTASSIUM CHANNELS; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; STAPHYLOCOCCUS AUREUS; STRUCTURE-ACTIVITY RELATIONSHIP; TERFENADINE; TOPOISOMERASE II INHIBITORS;

EID: 84908388258     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5010682     Document Type: Article

References (59)

1. Hidron, A. I.; Edwards, J. R.; Patel, J.; Horan, T. C.; Sievert, D. M.; Pollock, D. A.; Fridkin, S. K. Antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007 Infect. Control Hosp. Epidemiol. 2008, 29, 996-1011
2. Klevens, R.; Morrison, M. A.; Nadle, J.; Petit, S.; Gershman, K.; Ray, S.; Harrison, L. H.; Lynfield, R.; Dumyati, G.; Townes, J. M.; Craig, A. S.; Zell, E. R.; Fosheim, G. E.; McDougal, L. K.; Carey, R. B.; Fridken, S. K. Invasive methicillin-resistant Staphylococcus aureus infections in the United States JAMA, J. Am. Med. Assoc. 2007, 298, 1763-1771
3. Kim, J.; Lee, D.; Park, C.; So, W.; Jo, M.; Ok, T.; Kwon, J.; Kong, S.; Jo, S.; Kim, Y.; Choi, J.; Kim, H. C.; Ko, Y.; Choi, I.; Park, Y.; Yoon, J.; Ju, M. K.; Kim, J.; Han, S.-J.; Kim, T.-H.; Cechetto, J.; Nam, J.; Sommer, P.; Liuzzi, M.; Lee, J.; No, Z. Discovery of phenylaminopyridine derivatives as novel HIV-1 non-nucleoside reverse transcriptase inhibitors ACS Med. Chem. Lett. 2012, 3, 678-682
4. Shalit, I.; Berger, S.; Gorea, A.; Frimerman, H. Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital Antimicrob. Agents Chemother. 1989, 33, 593-594
5. Boucher, H. W.; Talbot, G. H.; Bradley, J. S.; Edwards, J. E.; Gilbert, D.; Rice, L. B.; Scheld, M.; Spellberg, B.; Bartlett, J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America Clin. Infect. Dis. 2009, 48, 1-12
6. Scheld, W. M. Maintaining fluoroquinolone class efficacy: review of influencing factors Emerg. Infect. Dis. 2003, 9, 1-9
7. Jacoby, G. A. Mechanisms of resistance to quinolones Clin. Infect. Dis. 2005, 41, S120-S126
8. Mitscher, L. A. Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents Chem. Rev. 2005, 105, 559-592
9. Harnett, N.; Brown, S.; Krishnan, C. Emergence of quinolone resistance among clinical isolates of methicillin-resistant Staphylococcus aureus in Ontario, Canada Antimicrob. Agents Chemother. 1991, 35, 1911-1913
10. Black, M. T.; Stachyra, T.; Platel, D.; Girard, A.-M.; Claudon, M.; Bruneau, J.-M.; Miossec, C. Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases Antimicrob. Agents Chemother. 2008, 52, 3339-3349
11. Basarab, G. S.; Manchester, J. I.; Bist, S.; Boriack-Sjodin, P. A.; Dangel, B.; Illingworth, R.; Sherer, B. A.; Sriram, S.; Uria-Nickelsen, M.; Eakin, A. E. Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents J. Med. Chem. 2013, 56, 8712-8735
12. Brvar, M.; Perdih, A.; Renko, M.; Anderluh, G.; Turk, D.; Solmajer, T. Structure-based discovery of substituted 4,5′-bithiazoles as novel DNA gyrase inhibitors J. Med. Chem. 2012, 55, 6413-6426
13. Reck, F.; Alm, R. A.; Brassil, P.; Newman, J. V.; Ciaccio, P.; McNulty, J.; Barthlow, H.; Goteti, K.; Breen, J.; Comita-Prevoir, J.; Cronin, M.; Ehmann, D. E.; Geng, B.; Godfrey, A. A.; Fisher, S. L. Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced p K a: antibacterial agents with an improved safety profile J. Med. Chem. 2012, 55, 6916-6933
14. Gillaspy, A. F.; Hickmon, S. G.; Skinner, R. A.; Thomas, J. R.; Nelson, C. L.; Smeltzer, M. S. Role of the accessory gene regulator (agr) in pathogenesis of staphylococcal osteomyelitis Infect. Immun. 1995, 63, 3373-3380
15. Reck, F.; Alm, R.; Brassil, P.; Newman, J.; DeJonge, B.; Eyermann, C. J.; Breault, G.; Breen, J.; Comita-Prevoir, J.; Cronin, M. Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II: broad-spectrum antibacterial agents with reduced hERG activity J. Med. Chem. 2011, 54, 7834-7847
16. Bax, B. D.; Chan, P. F.; Eggleston, D. S.; Fosberry, A.; Gentry, D. R.; Gorrec, F.; Giordano, I.; Hann, M. M.; Hennessy, A.; Hibbs, M.; Huang, J.; Jones, E.; Jones, J.; Brown, K. K.; Lewis, C. J.; May, E. W.; Saunders, M. R.; Singh, O.; Spitzfaden, C. E.; Shen, C.; Shillings, A.; Theobald, A. J.; Wohlkonig, A.; Pearson, N. D.; Gwynn, M. N. Type IIA topoisomerase inhibition by a new class of antibacterial agents Nature 2010, 466, 935-940
17. Coates, A. M.; Halls, G. Antibiotics in Phase II and II clinical trials. In Antibiotic Resistance; Coates, A. R. M., Ed.; Springer: Berlin, Heidelberg, 2012; Vol. 211, pp 167-183.
18. Projan, S. J. Why is big pharma getting out of antibacterial drug discovery Curr. Opin. Microbiol. 2003, 6, 427-430
19. White, A. R.; Blaser, M.; Carrs, O.; Cassell, G.; Fishman, N.; Guidos, R.; Levy, S.; Powers, J.; Norrby, R.; Tillotson, G. Effective antibacterials: at what cost? The economics of antibacterial resistance and it's control J. Antimicrob. Chemother. 2011, 66, 1948-1953
20. Aubé, J. Drug repurposing and the medicinal chemist ACS Med. Chem. Lett. 2012, 3, 442-444
21. Oprea, T. I.; Bauman, J. E.; Bologa, C. G.; Buranda, T.; Chigaev, A.; Edwards, B. S.; Jarvik, J. W.; Gresham, H. D.; Haynes, M. K.; Hjelle, B.; Hromas, R.; Hudson, L.; Mackenzie, D. A.; Muller, C. Y.; Reed, J. C.; Simons, P. C.; Smagley, Y.; Strouse, J.; Surviladze, Z.; Thompson, T.; Ursu, O.; Waller, A.; Wandinger-Ness, A.; Winter, S. S.; Wu, Y.; Young, S. M.; Larson, R. S.; Willman, C.; Sklar, L. A. Drug repurposing from an academic perspective Drug Discovery Today: Ther. Strat. 2011, 8, 61-69
22. Ashburn, T. T.; Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs Nature Rev. Drug Discovery 2004, 3, 673-683
23. Huang, R.; Southall, N.; Wang, Y.; Yasgar, A.; Shinn, P.; Jadhav, A.; Nguyen, D.-T.; Austin, C. P. The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics Sci. Transl. Med. 2011, 3, 80ps16
24. Jacobs, A. C.; DiDone, L.; Jobson, J.; Sofia, M. K.; Krysan, D.; Dunman, P. M. Adenylate kinase release as a high-throughput-screening-compatible reporter of bacterial lysis for identification of antibacterial agents Antimicrob. Agents Chemother. 2013, 57, 26-36
25. Woosley, R. L.; Chen, Y.; Freiman, J. P.; Gillis, R. A. Mechanism of the cardiotoxic actions of terfenadine JAMA, J. Am. Med. Assoc. 1993, 269, 1532-1536
26. Monahan, B. P.; Ferguson, C. L.; Killeavy, E. S.; Lloyd, B. K.; Troy, J.; Cantilena, L. R. Torsades de pointes occurring in association with terfenadine use JAMA, J. Am. Med. Assoc. 1990, 264, 2788-2790
27. Roy, M.-L.; Dumaine, R.; Brown, A. M. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine Circulation 1996, 94, 817-823
28. CLSI Performance Standards for Antimicrobial Susceptibility Testing: 23rd Informational Supplement, M100; Clinical Laboratory Standards Institute (CLSI): Wayne, PA, 2013.
29. DeMartino, J. K.; Hwang, I.; Connelly, S.; Wilson, I. A.; Boger, D. L. Asymmetric synthesis of inhibitors of glycinamide ribonucleotide transformylase J. Med. Chem. 2008, 51, 5441-5448
30. Moseley, J. D.; Murray, P. M.; Turp, E. R.; Tyler, S. N.; Burn, R. T. A mild robust generic protocol for the Suzuki reaction using an air stable catalyst Tetrahedron 2012, 68, 6010-6017
31. Honig, P. K.; Woosley, R. L.; Zamani, K.; Conner, D. P.; Cantilena, L. R. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin Clin. Pharmacol. Ther. 1992, 52, 231-238
32. Kawai, S. H.; Hambalek, R. J.; Just, G. A facile synthesis of an oxidation product of terfenadine J. Org. Chem. 1994, 59, 2620-2622
33. Zhu, R.; Xing, L.; Wang, X.; Cheng, C.; Su, D.; Hu, Y. Highly Practical "Ligand-Free-Like" Copper-Catalyzed N-Arylation of Azoles in Lower Nitrile Solvents Adv. Synth. Catal. 2008, 350, 1253-1257
34. Zhang, M. Q.; ter Laak, A. M.; Timmerman, H. Structure-activity relationships within a series of analogues of the histamine H1-antagonist terfenadine Eur. J. Med. Chem. 1993, 28, 165-173
35. Barnes-Seeman, D.; Jain, M.; Bell, L.; Ferreira, S.; Cohen, S.; Chen, X.-H.; Amin, J.; Snodgrass, B.; Hatsis, P. Metabolically stable tert -butyl replacement ACS Med. Chem. Lett. 2013, 4, 514-516
36. Wuitschik, G.; Carreira, E. M.; Wagner, B. r.; Fischer, H.; Parrilla, I.; Schuler, F.; Rogers-Evans, M.; Müller, K. Oxetanes in drug discovery: structural and synthetic insights J. Med. Chem. 2010, 53, 3227-3246
37. Lee, J.; Kang, S.-U.; Lim, J.-O.; Choi, H.-K.; Jin, M.-k.; Toth, A.; Pearce, L. V.; Tran, R.; Wang, Y.; Szabo, T.; Blumberg, P. M. N -[4-(Methylsulfonylamino)benzyl]thiourea analogues as vanilloid receptor antagonists: analysis of structure-activity relationships for the C-region Bioorg. Med. Chem. 2004, 12, 371-385
38. Edgar, D. M.; Hangauer, D. G.; Leighton, H. J.; Mignot, E. J. M.; Methods of treating sleep disorders. PCT patent WO2003032912A2, 2003.
39. Wu, Y.; Tai, H.-H.; Cho, H. Synthesis and SAR of thiazolidinedione derivatives as 15-PGDH inhibitors Bioorg. Med. Chem. 2010, 18, 1428-1433
40. Waring, M. J.; Johnstone, C. A quantitative assessment of hERG liability as a function of lipophilicity Bioorg. Med. Chem. Lett. 2007, 17, 1759-1764
41. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nature Rev. Drug Discovery 2007, 6, 881-890
42. Tetko, I. V. Computing chemistry on the web Drug Discovery Today 2005, 10, 1497-1500
43. Tetko, I. V.; Gasteiger, J.; Todeschini, R.; Mauri, A.; Livingstone, D.; Ertl, P.; Palyulin, V. A.; Radchenko, E. V.; Zefirov, N. S.; Makarenko, A. S. Virtual computational chemistry laboratory - design and description J. Comput.-Aided Mol. Des. 2005, 19, 453-463
44. Schröder, W.; Goerke, C.; Wolz, C. Opposing effects of aminocoumarins and fluoroquinolones on the SOS response and adaptability in Staphylococcus aureus J. Antimicrob. Chemother. 2013, 68, 529-538
45. Peng, Q.; Zhou, S.; Yao, F.; Hou, B.; Huang, Y.; Hua, D.; Zheng, Y.; Qian, Y. Baicalein suppresses the SOS response system of Staphylococcus aureus induced by ciprofloxacin Cell. Physiol. Biochem. 2011, 28, 1045-1050
46. Waring, M. J. Lipophilicity in drug discovery Expert Opin. Drug Discovery 2010, 5, 235-248
47. Eakin, A. E.; Green, O.; Hales, N.; Walkup, G. K.; Bist, S.; Singh, A.; Mullen, G.; Bryant, J.; Embrey, K.; Gao, N. Pyrrolamide DNA gyrase inhibitors: fragment-based nuclear magnetic resonance screening to identify antibacterial agents Antimicrob. Agents Chemother. 2012, 56, 1240-1246
48. Kazakova, S.; Hageman, J.; Matava, M.; Srinivasan, A.; Phelan, L.; Garfinkel, B.; Boo, T.; McAllister, S.; Anderson, J.; Jensen, B.; Dodson, D.; Lonsway, D.; McDougal, L.; Arduino, M.; Fraser, V.; Killgore, G.; Tenover, F. C.; Cody, S.; Jernigan, D. A clone of methicillin-resistant Staphylococcus aureus among professional football players N. Engl. J. Med. 2005, 352, 468-475
49. Hiramatsu, K.; Hanaki, H.; Ino, T.; Yabuto, K.; Oguri, T.; Tenover, F. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility Antimicrob. Chemother. 1997, 40, 135-136
50. Sievert, D.; Boulton, M.; Stolman, G.; Johnson, D.; Stobierski, M.; Downes, F.; Somsel, P.; Rudrik, J.; Brown, W.; Hafeez, W.; Lundstrom, T.; Flanagan, E.; Johnson, R.; Mitchell, J.; Chang, S. Staphylococcus aureus resistant to vancomycin MMWR Morb. Mortal. Wkly. Rep. 2002, 51, 565-567
51. Murray, B. E.; Singh, K. V.; Ross, R. P.; Heath, J. D.; Dunny, G. M.; Weinstock, G. M. Generation of restriction map of Enterococcus faecalis strain OG1 and investigation of growth requirements and regions encoding biosynthetic function J. Bacteriol. 1993, 175, 5216-5223
52. Jacobs, A. C.; Hood, I.; Boyd, K. L.; Olson, P. D.; Morrison, J. M.; Carson, S.; Sayood, K.; Iwen, P. C.; Skaar, E. R.; Dunman, P. M. Inactivation of phospholipase D diminishes Acinetobacter baumannii pathogenesis Infect. Immun. 2010, 78, 1952-1962
53. Pomakova, D. K.; Hsiao, C. B.; Beanan, J. M.; Olson, R.; MacDonald, U.; Keynan, Y.; Russo, T. A. Clinical and phenotypic differences between classis and hypervirulent Klebsiella pneumoniae: an emerging and under-recognized pathogenic variant Eur. J. Clin. Microbiol. Infect. Dis. 2012, 31, 981-989
54. Sambandamurthy, V. K.; Wang, X.; Chen, B.; Russell, R. G.; Derrick, S.; Collins, F. M.; Morris, S. L.; Jacobs, W. R., Jr. A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis Nat. Med. 2002, 8, 1171-1174
55. Sumandeep, K. G.; Garcia, G. A. Rifamycin inhibition of WT and Rifresistant Mycobacterium tuberculosis and Escherichia coli RNA polymerases in vitro Tuberculosis 2011, 91, 361-369
56. Franzblau, S. G.; Witzig, R. S.; McLaughlin, J. C.; Torres, P.; Madico, G.; Hernandez, A.; Degnan, M. T.; Cook, M. B.; Quenzer, V. K. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay J. Clin. Microbiol. 1998, 36, 362-366
57. Anderson, K. L.; Roberts, C.; Disz, T.; Vonstein, V.; Hwang, K.; Overbeek, R.; Olsen, P. D.; Projan, S. J.; Dunman, P. M. Characterization of the Staphylococcus aureus heat shock, cold shock, stringent, and SOS responses and their effects on log-phase mRNA turnover J. Bacteriol. 2006, 188 (19) 6739-6756
58. Utaida, S.; Dunman, P. M.; Macapagal, D.; Murphy, E.; Projan, S. J.; Singh, V. K.; Jayaswal, R. K.; Wilkinson, B. J. Genome-wide transcriptional profiling of the response of Staphylococcus aureus to cell-wall-active antibiotics reveals a cell-wall-stress stimulon Microbiology 2003, 149 (10) 2719-2732
59. Finlayson, K.; Turnbull, L.; January, C. T.; Sharkey, J.; Kelly, J. S. [3H]Dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen Eur. J. Pharmacol. 2001, 430, 147-148